Published in Blood, this article presents initial findings from a proof-of-concept study led by Martin Wermke, MD, from the Technical University of Dresden in Germany. The UniCAR platform uses targeting molecule TM123 and a single-chain variable fragment that is directed against the CD123 antigen, offering a potential new treatment option for patients with relapsed/refractory acute myeloid leukemia (AML).

In this JAMA Surgery Original Investigation, the researchers fielded a Swedish cohort study of 48,986 women to discover whether breast conservation offers a survival benefit compared with mastectomy when results are adjusted for main confounders such as comorbidity and socioeconomic status. The main outcomes and measures were overall survival (OS) and breast cancer–specific survival (BCSS).

According to new research from the University of East Anglia (UEA) and published in the journal Proceedings of the Royal Society B, food intake has a detrimental effect on three generations of offspring—particularly when those descendants have access to unlimited food. They learned this through the study of food intake in 2,500 roundworms (Caenorhabditis elegans) split across four generations.

From new scams like unproven COVID-19 treatments to the returns-like-a-bad-penny “Diabetes Fast Fixes,” health product swindles are unfortunately part of the world we live in. The too-good-to-be-true claims allure many patients suffering from debilitating conditions, and at best, it may be just a waste of money. At worst, though, some of these products could cause serious problems and possibly even death.

This article dives into information and the causes of five drug-induced diseases (DIDs) including hyponatremia/SIADH, pulmonary disease, GI bleeding, QT prolongation/Torsades de pointes, and hypoglycemia. Because research reviewed by the FDA for drug approval does not always include DIDs, it is the physician’s responsibility to monitor for DIDs and think twice about prescribing agents that could lead to DIDs.

As a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in metastatic urothelial carcinoma (mUC), sacituzumab govitecan (SG) – brand name Trodelvy –was evaluated and compared to current treatments to gauge whether SG objective response rates (ORRs) and median overall survival (OS) outperform the average of 10% ORR and 7 to 8 months OS.